ImVisioN Therapeutics Starts Phase I Clinical Trial Of IVN201 Against Cat Dander Allergy And Raises CHF 4.6 M

ImVisioN Therapeutics AG., a biopharmaceutical company pioneering intralymphatic immunotherapy (ILIT?), announced that it has enrolled the first patient for a Phase I clinical study of its lead product IVN201, an immunotherapeutic product for cat dander allergy. The Company also announced the closing of a Series A Financing round of CHF 4.6 M, allowing the clinical development of IVN201.

More: continued here

Filed under: Allergies on September 12th, 2008